The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Project description

Early detection of cardiac ischaemia

Cardiac ischaemia occurs when the blood flow to the heart is reduced often due to atherosclerosis, the formation of cholesterol plaques blocking one of the central arteries. Ischaemia can have serious complications, including heart attacks and the ensuing irreversible damage that can lead to heart failure. To prevent heart damage progression, the EU-funded AGLYC project has developed a first-class blood-based biomarker for early detection of ischaemia before irreversible injury of the heart. The biomarker test will be easy to use, sensitive and cost-effective, and will improve the early diagnosis of ischaemic episodes. Given that cardiovascular diseases are the leading cause of morbidity and mortality worldwide, implementation of the AGLYC biomarker is expected to positively impact patient lives.

Fields of science

• social sciences › economics and business › business and management › business models
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

GLYCARDIAL DIAGNOSTICS, SL

Net EU contribution

€ 1 908 997,30

Address

Calle Baldiri Reixac 48 - Planta 1 Puerta B04 Parc Cientific De Barcelona Torre R
08028 Barcelona
Spain

Region

Este › Cataluña › Barcelona

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 818 141,70